Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Published:2021-11 Issue:11 Volume:22 Page:1582-1596
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Facon Thierry,Kumar Shaji K,Plesner Torben,Orlowski Robert Z,Moreau Philippe,Bahlis Nizar,Basu Supratik,Nahi Hareth,Hulin Cyrille,Quach Hang,Goldschmidt Hartmut,O'Dwyer Michael,Perrot Aurore,Venner Christopher P,Weisel Katja,Mace Joseph R,Raje Noopur,Tiab Mourad,Macro Margaret,Frenzel Laurent,Leleu Xavier,Ahmadi Tahamtan,Wang Jianping,Van Rampelbergh Rian,Uhlar Clarissa M,Tromp Brenda,Delioukina Maria,Vermeulen Jessica,Usmani Saad Z

Funder

Janssen Research and Development LLC

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;de Weers;J Immunol,2011

2. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking;Overdijk;J Immunol,2016

3. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

4. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

3. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation;Frontiers in Hematology;2024-09-11

4. Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma;American Journal of Hematology;2024-09-10

5. Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era;Clinical and Experimental Medicine;2024-09-09